-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
WIN 54954
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/107355-45-3.gif)
| Category | Enterovirus (EV) |
| CAS | 107355-45-3 |
| Description | WIN 54954, an orally active and broad-spectrum anti-picornavirus drug, is effective against human rhinovirus, echovirus 9, and enterovirus infections. |
Product Information
| Synonyms | 5-(5-(2,6-Dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methylisoxazole; Isoxazole, 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-methyl-; 5-{5-[2,6-dichloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole |
| IUPAC Name | 5-[5-[2,6-dichloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl]-3-methyl-1,2-oxazole |
| Molecular Weight | 383.27 |
| Molecular Formula | C18H20Cl2N2O3 |
| Canonical SMILES | CC1=NOC(=C1)CCCCCOC2=C(C=C(C=C2Cl)C3=NCCO3)Cl |
| InChI | InChI=1S/C18H20Cl2N2O3/c1-12-9-14(25-22-12)5-3-2-4-7-23-17-15(19)10-13(11-16(17)20)18-21-6-8-24-18/h9-11H,2-8H2,1H3 |
| InChIKey | JJDHAOLOHQTGMG-UHFFFAOYSA-N |
| Boiling Point | 555.4±50.0°C at 760 mmHg |
| Purity | ≥98% |
| Density | 1.4±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Store at 2-8°C, protect from light |
| Complexity | 440 |
| Exact Mass | 382.0850979 |
| In Vitro | WIN 54954 reduces plaque formation of 50 of 52 rhinovirus serotypes (MICs ranges from 0.007 to 2.2 μg/mL).WIN 54954 inhibits 15 commonly isolated enteroviruses, with an EC80 of 0.06 μg/mL |
| In Vivo | WIN 54954 (2-100 mg/kg; p.o.) protects 50% of the mice from developing paralysis following infection with coxsackievirus 9 and echovirus-9 at the dose of 2 and 100 mg/kg, respectively. |
| PSA | 56.85000 |
| Target | Enterovirus |
| XLogP3-AA | 4.6 |
